CytomX Therapeutics, Inc.
Here’s whether CytomX Therapeutics, Inc. (CTMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 44 — healthy momentum range; strong 1-year return of +452.0%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.30% over 10 days); 3-month momentum negative (-31.4%); declining volume on rally — weak conviction (0.66x 30d avg). Currently 49.1% off its 52-week high. Score: +0/7.
CTMX is holding above its long-term 200-day MA ($3.84) but has slipped below the 50-day MA ($4.74), pointing to short-term weakness in an otherwise intact trend. An RSI of 43.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +452.0% compares to +22.9% for SPY (beat the market by 429.1%). The current 49.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.